Healthcare [ 7/13 ] | Biotechnology [ 61/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 3, 24 | -0.09 Decreased by -80% | -0.07 Decreased by -28.57% |
| Mar 28, 24 | -0.09 Decreased by -50% | -0.06 Decreased by -50% |
| Nov 13, 23 | -0.05 Increased by +16.67% | -0.07 Increased by +28.57% |
| Aug 14, 23 | -0.08 Decreased by -60% | -0.06 Decreased by -33.33% |
| May 15, 23 | -0.05 Decreased by -25% | -0.06 Increased by +16.67% |
| Mar 22, 23 | -0.06 Decreased by -50% | -0.06 |
| Nov 7, 22 | -0.06 Decreased by -50% | -0.06 |
| Aug 8, 22 | -0.05 Increased by +16.67% | -0.06 Increased by +16.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | N/A Decreased by N/A% | -7.75 M Decreased by -13.3% | - - |
| Sep 30, 23 | 0 Decreased by N/A% | -6.23 M Increased by +20.31% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0 Decreased by N/A% | -9.83 M Decreased by -45.65% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0 Decreased by N/A% | -5.46 M Decreased by -13.18% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0 Decreased by N/A% | -6.84 M Decreased by -41.65% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0 Decreased by N/A% | -7.82 M Decreased by -50.41% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0 Decreased by N/A% | -6.75 M Increased by +4.12% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0 Decreased by N/A% | -4.83 M Decreased by -36.37% | Decreased by N/A% Decreased by N/A% |
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.